Capricor Therapeutics Inc CAPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
-
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
-
Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7
-
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
-
Capricor Therapeutics Shares Rise 7% After Collaboration for Covid-19 Vaccine
Trading Information
- Previous Close Price
- $9.99
- Day Range
- $9.05–10.30
- 52-Week Range
- $2.68–12.87
- Bid/Ask
- $10.00 / $10.08
- Market Cap
- $351.61 Mil
- Volume/Avg
- 2.6 Mil / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 102
- Website
- https://www.capricor.com
Comparables
Valuation
|
Metric
|
CAPR
|
EWTX
|
CRMD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 27.67 | 4.79 | 9.63 |
Price/Sales | 10.97 | — | 572.38 |
Price/Cash Flow | — | — | — |
Price/Earnings
CAPR
EWTX
CRMD
Financial Strength
|
Metric
|
CAPR
|
EWTX
|
CRMD
|
|---|---|---|---|
Quick Ratio | 1.33 | 29.79 | 4.12 |
Current Ratio | 1.37 | 30.24 | 4.79 |
Interest Coverage | — | — | −1,599.40 |
Quick Ratio
CAPR
EWTX
CRMD
Profitability
|
Metric
|
CAPR
|
EWTX
|
CRMD
|
|---|---|---|---|
Return on Assets (Normalized) | −41.25% | −23.23% | −66.44% |
Return on Equity (Normalized) | −177.10% | −24.43% | −77.20% |
Return on Invested Capital (Normalized) | −147.50% | −29.19% | −81.35% |
Return on Assets
CAPR
EWTX
CRMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ldfxcrlgm | Tyts | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lkxnlrkv | Trycrs | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Frlmmjbzy | Vrtwzj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wcskdtyxr | Vbxbp | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Yhfqkrqg | Lbwn | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Zfbvryqv | Xxmhz | $28.1 Bil | |||
| Moderna Inc
MRNA
| Pnngycbr | Tfsz | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Mbgprxvn | Jtbq | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xspqqckh | Fkppnr | $13.4 Bil | |||
| Incyte Corp
INCY
| Qpnsmftk | Ccbyhx | $12.7 Bil |
United States